Quantcast
Last updated on April 18, 2014 at 11:05 EDT

ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory

February 28, 2013

BUDAPEST, Hungary, BRUSSELS & LEIDEN, The Netherlands, February 28, 2013 /PRNewswire/ –

ChemAxon [http://www.chemaxon.com/#_blank ], a leader in providing chemistry software
solutions and consulting services for life science research, and the European Lead
Factory, a novel platform for innovative drug discovery, announces that ChemAxon will
provide the core tools and leads the development of the informatics platform to support
the panEuropean initiative.

ChemAxon will be building a portal to support the crowd-sourcing initiative using its
core JChem Base and Marvin components. The scientific decision process involved in
selecting the right proposals from those submitted will be supported by ChemAxon’s
Discovery Toolkit, including various fingerprints and physico-chemical property
predictors. The portal will also offer a way for submitters to keep track of their
submission’s status and for the consortium’s selection committee to score and analyze
submitted proposals.

The Innovative Medicines Initiative (IMI), the world’s largest public-private
initiative in the field of pharmaceutical research aims to create a new and unique
collaboration of public and private sector. The research program of up to EUR 196 million
and named the European Lead Factory, involving small and medium-sized enterprises (SMEs),
academic institutions and large pharmaceutical companies, aims to improve the
competitiveness of the European pharmaceutical industry, accelerate the drug development
process, and strives to develop safer, more effective drugs.

The European Lead Factory was launched by an international consortium of 30 partners,
with the only Hungarian participant being ChemAxon Ltd. This partnership, the first of its
kind, is supported by the Innovative Medicines Initiative (IMI) and creates unprecedented
opportunities for the discovery of new medicines through access to a collection of small
molecules contributed by pharmaceutical companies, and a newly synthesized compound
collection built by the SMEs and academic institutions.

As a result of this partnership, the new compound library consisting of up to half a
million compounds will be accessible to all project partners and to public organizations.
Screening of this compound collection will be performed within the pharmaceutical
companies and by a newly established European Screening Centre, which will run state of
the art facilities in Scotland and the Netherlands to handle logistics and screening of
compound libraries.

If the project proves successful during its initial five year funding period, the
partnership aims for a sustainable role in drug discovery in Europe.

Notes to Editors

The research leading to these results has received support from the Innovative
Medicines Initiative Joint Undertaking under grant agreement ndegree(s) 115489, resources
of which are composed of financial contribution from the European Union’s Seventh
Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

IMI’s full press release to be found at:

http://www.chemaxon.com/wp-content/uploads/2013/02/PressRelease_EuropeanLeadFactory_Final.pdf

About ChemAxon

ChemAxon [http://www.chemaxon.com ] is a leader in providing cheminformatics software
platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical
industries. With core capabilities for structure visualization, search and management,
property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon
active interaction with users and software portability to create powerful, cost effective
cross platform solutions that power modern cheminformatics and chemical communication. The
company is privately owned with European headquarters in Budapest, US East Coast
headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across
North America.

SOURCE ChemAxon


Source: PR Newswire